肿瘤细胞治疗研究
英文原题：Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
根据近期研究，双特异性抗体（BsAbs）是一种有前景的新型免疫治疗方法。
近期研究显示，双特异性抗体（BsAb）是一种有前景的新型免疫疗法，其形式仍在不断开发。仅2022年，就有四种BsAb获批临床应用：tebentafusp、faricimab、mosunetuzumab和teclistamab。odronextamab、talquetamab、linvoseltamab和elranatamab等BsAb也正在多项临床研究中积极评估。初步结果显示，这些疗法在复发或难治性滤泡性淋巴瘤（RRFL）、复发或难治性弥漫性大B细胞淋巴瘤（RRDLBCL）和复发或难治性多发性骨髓瘤（RRMM）中应答率令人鼓舞，尤其适用于既往接受多线治疗的患者，包括蛋白酶体抑制剂、免疫调节药物、抗CD38抗体和CAR-T治疗后进展者。本文总结了2023年6月8日至11日在德国法兰克福举行的第28届欧洲血液学协会（EHA）年会公布的BsAb单药或联合治疗RRFL、RRDLBCL及RRMM数据。
According to recent research, bispecific antibodies (BsAbs) are a promising new immunotherapy method. Various BsAb forms are constantly being developed. In the year 2022 alone, four BsAbs (tebentafusp, faricimab, mosunetuzumab, and teclistamab) were approved for clinical applications. BsAbs including odronextamab, talquetamab, linvoseltamab, and elranatamab are being actively evaluated in different clinical studies. Preliminary results show promising response rates in relapsed/refractory follicular lymphoma (RRFL), relapsed/refractory diffuse large B-cell lymphoma (RRDLBCL), and relapsed/refractory multiple myeloma (RRMM), especially in heavily pretreated patients, including those who have progressed after proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, and CAR-T therapies. We summarized data published at the 28th European Hematology Association (EHA) annual meeting, which was held in Frankfurt between 8 June 2023 and 11 June 2023 on BsAbs monotherapy or combination therapy for RRFL, RRDLBCL, and RRMM.
MEMBER ACCOUNT
登录成功会直接打开下一页。
